Four types of PE exemption drugs listed in one month…

By Eo, Yun-Ho | translator Alice Kang

22.03.27 13:34:42

가나다라 0

Kymriah, Rozlytrek, Vitrakvi listed in April after Xospata's listing in March

First-ever treatment option to be introduced in each area… succeeds in listing despite after overcoming discussions

Coverage expansions of new drugs continue to be reported. In fact, four new drugs were successfully listed last month.

According to industry sources, starting with Astellas’ ‘Xospata (gilteritinib)’ in March, Novartis’s ‘Kymirah (tisagenlecleucel),’ Roche’s ‘Rozlytrek (entrectinib),’ Bayer’s ‘Vitrakvi (larotrectinib)’ were listed as new drugs under the pharmacoevaluation exemption track.

Despite the difficulties faced during discussions, all the drugs were successfully listed in the end.

◆'Xospata’ resolves the unmet needs in leukemia

Xospata is the first treatment approved for FLT3mut+ relapsed/refractory Acute Myeloid Leukemia (AML).
Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)